Just weeks after being acquired by Allergan, the team behind Chicago-based Naurex is launching a new startup: Aptinyx. It'll focus on developing drugs for diseases of the brain and nervous system.
Allergan is the center of attention in a couple of stories this morning with anti-depressant acquisition and a sale of its generics business to Teva.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The hallucinogenic drug ketamine, or Special K as it’s known on the street, has been used as an anesthetic for decades. Now, it’s being used to treat severe cases of depression – but there are some critics. Unlike other depression drugs like Prozac or Lexapro, ketamine is said to relieve symptoms in hours, not weeks. […]
Northwestern University biotech spinout Naurex just raised $80 million for its CNS drug that targets major depressive disorder – a real win for the psychiatric med space, which has few significant contenders at present. The money’s meant to further develop GLYX-13, an NMDA receptor modulator that’s on the cusp of entering Phase III trials to treat major […]